Gastric Cancer (Diagnosis)
Conditions
Brief summary
This study focuses on the discovery of protein biomarkers for the early diagnosis of gastric cancer and the development of corresponding detection methods. By employing advanced mass spectrometry-based proteomic technologies, the investigators conducted an in-depth analysis of a large cohort of clinical samples to identify specific protein biomarkers capable of accurately distinguishing gastric cancer patients from healthy individuals. The findings from this research are expected to facilitate the development of novel non-invasive or minimally invasive diagnostic approaches, thereby improving early detection, enhancing patient prognosis, and increasing survival rates.
Interventions
None listed
Sponsors
Shanghai Zhongshan Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
Yes
Inclusion criteria
Gastric cancer patients enrolled in this study must meet all of the following criteria: 1. Male or female, aged ≥18 and ≤95 years. 2. Histopathologically confirmed gastric cancer, as defined by the 2024 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer. 3. No prior anti-tumor treatment (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy). 4. Availability of complete clinicopathological data and follow-up information. Patients with precancerous gastric lesions must meet all of the following criteria: 1. Male or female, aged ≥18 and ≤95 years. 2. Histopathologically confirmed absence of gastric cancer. 3. Diagnosis consistent with precancerous gastric lesions as defined by the American Society for Gastrointestinal Endoscopy (ASGE, 2015 edition). 4. Availability of complete clinicopathological data and follow-up information. Healthy controls must meet all of the following criteria: 1. Male or female, aged ≥18 and ≤95 years. 2. Histopathologically confirmed absence of gastric cancer. 3. No evidence of precancerous gastric lesions. 4. Availability of complete clinicopathological data and follow-up information.
Exclusion criteria
Patients meeting any of the following conditions will be excluded: 1. History of prior malignancy or cancer treatment. 2. Presence of concurrent malignancies of other types. 3. Inability to tolerate gastroscopy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic Performance of the Serum Protein Biomarker-Based Model for Gastric Cancer | 3 years | Evaluation of the sensitivity and specificity of a diagnostic model constructed using key serum protein biomarkers for the early detection of gastric cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Predictive performance of the serum protein model for the progression risk from precancerous gastric lesions to gastric cancer | 3 years | Predictive performance of the serum protein model for the progression risk from precancerous gastric lesions to gastric cancer, evaluated by prediction accuracy and area under the ROC curve (AUC). |
| Predictive performance of the serum protein model for response to neoadjuvant therapy in gastric cancer | 3 years | Predictive performance of the serum protein model for response to neoadjuvant therapy in gastric cancer, assessed by prediction accuracy and AUC. |
| Prognostic performance of the serum protein model in gastric cancer patients | 3 years | Prognostic performance of the serum protein model in gastric cancer patients, measured by prediction accuracy and AUC. |
Contacts
Primary ContactZhaoqing Tang
Outcome results
None listed